Cytokinetics Announces Closing of Public Offering of Common Stock

Group 1 - Cytokinetics, Incorporated has successfully closed its underwritten public offering of 9,803,922 shares of common stock at a price of $51.00 per share, resulting in gross proceeds of approximately $500 million before offering expenses [1][2][3] - The offering was managed by J.P. Morgan, Goldman Sachs & Co. LLC, and Morgan Stanley as joint book-running managers [2] - The securities were offered under a shelf registration statement filed with the SEC on November 18, 2022, which has become automatically effective [3]